Incorporating Genome-Based Technologies into Toxicology and Safety Assessments for Drug Discovery and Development

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International Journal of Pharmaceutical Medicine

• Publication date

  2007-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2165/00124363-200721060-00007
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer

  2008cited by this paper
• The nuclear receptor LXR is a glucose sensor

  2007cited by this paper
• Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan

  2007cited by this paper
• Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

  2007cited by this paper
• Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol

  2007cited by this paper
• Application of pharmacogenomics in drug discovery and development: correlations between transcriptional modulation and preclinical safety observations.

  2007cited by this paper
• Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: a long road with deep potholes.

  2007cited by this paper
• The Liver X Receptor (LXR) and Hepatic Lipogenesis

  2007cited by this paper
• CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications

  2006cited by this paper
• Studies on LXR- and FXR-mediated effects on cholesterol homeostasis in normal and cholic acid-depleted mice Published, JLR Papers in Press, November 1, 2005.

  2006cited by this paper
• [Pharmacogenetic testing: utility in drug development and in routine clinical practice].

  2006cited by this paper
• Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway

  2006cited by this paper
• Pharmacogenetics and the concept of individualized medicine

  2006cited by this paper
• The pharmocogenomics of warfarin: closing in on personalized medicine.

  2006cited by this paper
• Microarray Analysis of Lipopolysaccharide Potentiation of Trovafloxacin-Induced Liver Injury in Rats Suggests a Role for Proinflammatory Chemokines and Neutrophils

  2006cited by this paper
• Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis

  2006cited by this paper
• Pharmacogenomics and individualized drug therapy.

  2006cited by this paper
• Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.

  2006cited by this paper
• Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice.

  2006cited by this paper
• Development of a toxicogenomics in vitro assay for the efficient characterization of compounds.

  2006cited by this paper
• Pitavastatin Effect on ATP Binding Cassette A1-Mediated Lipid Efflux from Macrophages: Evidence for Liver X Receptor (LXR)-Dependent and LXR-Independent Mechanisms of Activation by cAMP

  2006cited by this paper
• CYP1A in TCDD Toxicity and in Physiology–with Particular Reference to CYP Dependent Arachidonic Acid Metabolism and other Endogenous Substrates

  2006cited by this paper
• The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995–2005

  2006cited by this paper
• A reporter gene cellular model for evaluating induction of CYP3A4 by new chemical entities

  2006cited by this paper
• Tests pharmacogénétiques : leur place en pratique médicale courante et dans le développement des médicaments

  2006cited by this paper
• Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver

  2006cited by this paper
• Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting

  2006cited by this paper
• Application of genomics in preclinical drug safety evaluation.

  2006cited by this paper
• Key Issues in the Role of Peroxisome Proliferator–Activated Receptor Agonism and Cell Signaling in Trichloroethylene Toxicity

  2006cited by this paper
• Prescribing BiDil: is it black and white?

  2006cited by this paper
• Benefit of farnesoid X receptor inhibition in obstructive cholestasis.

  2006cited by this paper
• Overview of the pharmacogenetics of HIV therapy

  2006cited by this paper
• Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.

  2006cited by this paper
• Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes.

  2006cited by this paper
• CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

  2006cited by this paper
• Effects of FXR in foam-cell formation and atherosclerosis development.

  2006cited by this paper
• Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity

  2006cited by this paper
• Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

  2006cited by this paper
• Assessment of hepatotoxic liabilities by transcript profiling.

  2005cited by this paper
• Cell-based models to study hepatic drug metabolism and enzyme induction in humans

  2005cited by this paper
• Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

  2005cited by this paper
• Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

  2005cited by this paper
• A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo.

  2005cited by this paper
• Preclinical Drug Safety Analysis by Chemogenomic Profiling in the Liver

  2005cited by this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cited by this paper
• Implications of pharmacogenomics for drug development and clinical practice.

  2005cited by this paper
• A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity

  2005cited by this paper
• Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: A prospective clinical study

  2005cited by this paper
• SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING

  2005cited by this paper
• Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?

  2005cited by this paper
• Gene expression profiling in streptozotocin treated mouse liver using DNA microarray.

  2005cited by this paper
• Morphological and gene expression analysis in mouse primary cultured hepatocytes exposed to streptozotocin.

  2005cited by this paper
• Systems biology in drug safety and metabolism: integration of microarray, real-time PCR and enzyme approaches.

  2005cited by this paper
• Synthetic LXR agonists increase LDL in CETP species Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500116-JLR200

  2005cited by this paper
• Elucidating mechanisms of drug-induced toxicity

  2005cited by this paper
• Pharmacogenetics and drug development: the path to safer and more effective drugs

  2004cited by this paper
• Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design.

  2004cited by this paper
• Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes

  2004cited by this paper
• Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

  2004cited by this paper
• Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

  2004cited by this paper
• Gene expression profile in the livers of rats orally administered ethinylestradiol for 28 days using a microarray technique.

  2004cited by this paper
• Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes.

  2004cited by this paper
• Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms

  2004cited by this paper
• cDNA microarray gene expression analysis and toxicological phenotype for anticancer drug.

  2004cited by this paper
• Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond.

  2004cited by this paper
• Toxicogenomics in predictive toxicology in drug development.

  2004cited by this paper
• Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

  2004cited by this paper
• Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

  2004cited by this paper
• Pharmacogenetics to Predict Drug-Related Adverse Events

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Guest Editorial: Regulatory Acceptance of Toxicogenomics Data

  2004cited by this paper
• Discriminating Different Classes of Toxicants by Transcript Profiling

  2004cited by this paper
• Monitoring therapy with gene expression profiling reveals physiological differences in drug action.

  2004cited by this paper
• Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes.

  2003cited by this paper
• Pharmacogenetics goes genomic

  2003cited by this paper
• PPARbeta regulates vitamin A metabolism-related gene expression in hepatic stellate cells undergoing activation.

  2003cited by this paper
• Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

  2003cited by this paper
• The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse Published, JLR Papers in Press, August 16, 2003. DOI 10.1194/jlr.M300135-JLR200

  2003cited by this paper
• Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen.

  2003cited by this paper
• Gene expression analysis of the acute phase response using a canine microarray.

  2003cited by this paper
• Effect of two 5-HT6 receptor antagonists on the rat liver: a molecular approach

  2003cited by this paper
• Inflammation and Drug Idiosyncrasy—Is There a Connection?

  2003cited by this paper
• Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis

  2003cited by this paper
• Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes

  2003cited by this paper
• Cytochrome P450 enzyme polymorphisms and adverse drug reactions.

  2003cited by this paper
• Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems.

  2003cited by this paper
• The Drugs Don't Work

  2003cited by this paper
• Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.

  2003cited by this paper
• Effect of caffeine on acetaminophen hepatotoxicity in cultured hepatocytes treated with ethanol and isopentanol.

  2002cited by this paper
• Development of a DNA Microarray for Toxicology Based on Hepatotoxin-Regulated Sequences

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• The path to personalized medicine.

  2002cited by this paper
• Toxicogenomics, Drug Discovery, and the Pathologist

  2002cited by this paper
• Transcriptomics in predictive toxicology.

  2002cited by this paper
• Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles*

  2002cited by this paper
• Synthetic LXR ligand inhibits the development of atherosclerosis in mice

  2002cited by this paper
• CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

  2002cited by this paper
• Are chemically reactive metabolites responsible for adverse reactions to drugs?

  2002cited by this paper
• Genomics and the prediction of xenobiotic toxicity.

  2002cited by this paper

• No citing papers are available for this paper.